NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 230)
Posted On: 03/12/2020 2:21:38 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Launch of New AI Platform for Vaccine and Drug Development Targeting COVID-19, MERS and SARS
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its plans to launch a new AI platform for vaccine and drug development targeting Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS and SARS) through an operating agreement with Soluble Therapeutics. According to the update, POAI has also signed a letter of intent with InventaBioTech to acquire Soluble Therapeutics, its assets and its HSCTM Technology. As global health experts predict an ever-increasing number of viral outbreaks like COVID-19, POAI is taking proactive measures to be part of the solution by applying artificial intelligence to aid in the development of new drugs and vaccines. Soluble’s computer system, utilizing its HSCTM technology and six machines, is expected to be able to run over 12,000 computer simulations per machine to help generate new diagnostics, vaccines and therapeutics. “Soluble has six customized machines in its facilities that can help identify the best solutions for vaccines, proteins or antibodies being developed to help fight the COVID-19 contagion,” Predictive Oncology CEO Carl Schwartz said in the news release. “Through this operating partnership and acquisition, we are ready to assist in the development of viable treatment options that use biological, complex ingredients and formulations to speed up the pre-clinical and clinical development of treatments.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its plans to launch a new AI platform for vaccine and drug development targeting Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS and SARS) through an operating agreement with Soluble Therapeutics. According to the update, POAI has also signed a letter of intent with InventaBioTech to acquire Soluble Therapeutics, its assets and its HSCTM Technology. As global health experts predict an ever-increasing number of viral outbreaks like COVID-19, POAI is taking proactive measures to be part of the solution by applying artificial intelligence to aid in the development of new drugs and vaccines. Soluble’s computer system, utilizing its HSCTM technology and six machines, is expected to be able to run over 12,000 computer simulations per machine to help generate new diagnostics, vaccines and therapeutics. “Soluble has six customized machines in its facilities that can help identify the best solutions for vaccines, proteins or antibodies being developed to help fight the COVID-19 contagion,” Predictive Oncology CEO Carl Schwartz said in the news release. “Through this operating partnership and acquisition, we are ready to assist in the development of viable treatment options that use biological, complex ingredients and formulations to speed up the pre-clinical and clinical development of treatments.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)